Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Life Sci. 2023 Mar 1;316:121399. doi: 10.1016/j.lfs.2023.121399. Epub 2023 Jan 14.
Macrophages play a major role in maintaining an organism's physiology, such as development, homeostasis, tissue repair, and immunity. These immune cells are known to be involved in tumor progression and modulation. Monocytes can be polarized to two types of macrophages (M1 macrophages and pro-tumor M2 macrophages). Through this article, we aim to emphasize the potential of targeting macrophages in order to improve current strategies for tumor management. Various strategies that target macrophages as a therapeutic target have been discussed along with ongoing clinical trials. We have discussed the role of macrophages in various stages of tumor progression epithelial-to-mesenchymal transition (EMT), invasion, maintaining the stability of circulating tumor cells (CTCs) in blood, and establishing a premetastatic niche along with the role of various cytokines and chemokines involved in these processes. Intriguingly macrophages can also serve as drug carriers due to their tumor tropism along the chemokine gradient. They surpass currently explored nanotherapeutics in tumor accumulation and circulation half-life. We have emphasized on macrophage-based biomimetic formulations and macrophage-hitchhiking as a strategy to effectively target tumors. We firmly believe that targeting macrophages or utilizing them as an indigenous carrier system could transform cancer management.
巨噬细胞在维持生物体的生理机能方面发挥着重要作用,如发育、稳态、组织修复和免疫。这些免疫细胞被认为参与了肿瘤的进展和调节。单核细胞可以极化为两种类型的巨噬细胞(M1 巨噬细胞和促肿瘤 M2 巨噬细胞)。通过本文,我们旨在强调靶向巨噬细胞的潜力,以改善当前的肿瘤管理策略。我们讨论了各种针对巨噬细胞作为治疗靶点的策略,以及正在进行的临床试验。我们讨论了巨噬细胞在肿瘤进展的各个阶段中的作用,包括上皮间质转化 (EMT)、侵袭、维持循环肿瘤细胞 (CTC) 在血液中的稳定性,以及建立前转移龛,以及涉及这些过程的各种细胞因子和趋化因子的作用。有趣的是,由于巨噬细胞沿着趋化因子梯度具有肿瘤趋向性,因此它们也可以作为药物载体。它们在肿瘤积累和循环半衰期方面超过了目前探索的纳米疗法。我们强调了基于巨噬细胞的仿生制剂和巨噬细胞搭便车作为一种有效靶向肿瘤的策略。我们坚信,靶向巨噬细胞或利用它们作为本土载体系统可以改变癌症的治疗方式。